Tag: ADCC assay

The Impact of Human Serum on ADCC Assays

3rd July 2018

Category: Bioanalytical

Tags: ,

By: Laura McAleer, Technical Services Scientist,

Antibody-Dependent Cellular Cytotoxicity (ADCC) is a mechanism adopted by the immune system to remove infected or cancerous cells. Antibodies bind a specific antigen on the target cell surface, which in turn binds the FcγRIIIa receptor on effector cells (e.g Natural Killer (NK) Cells) via the Fc region, resulting in the lysis of the target cell. Although in More

Piecing together the biosimilar puzzle: Physicochemical & Functional Analytics

27th March 2017

Category: Bioanalytical / Biosimilars

Tags: , , , , , , , ,

By: Dr Terry Gray, Field Marketing Manager,

Part two Read Part One. A fundamental feature of a mAb is its biological structure, as this defines the functional output of the biologic, as illustrated by Figure 2. Figure 2 – The interplay between the structure of a monoclonal antibody, the affinity for interaction and the resulting functional activity. Fundamentally, the sequence of a More

ELISA – Conception and Applications

19th August 2015

Category: Bioanalytical / Biosimilars

Tags: , ,

By: Laura McAleer, Technical Services Scientist,

Since its conception in the early 1970’s the Enzyme Linked Immunosorbent Assay (ELISA) has been a primary method of analyte detection. In its four decades it has become a fundamental tool in a wide range of scientific fields, its diverse nature demonstrated by its range of uses. The ELISA was the first screening test widely used More

An Orthogonal Approach to ADCC Biosimilar Testing

Category: Biosimilars

Tags: , ,

By: Debbie Allan PhD, Technical Services Scientist,

Antibody-Dependent Cellular Cytotoxicity (ADCC) is a mechanism adopted by the immune system to remove infected or cancerous cells. Antibodies bind a specific antigen on the target cell surface which in turn binds the FcγRIIIa receptor on effector cells (e.g. Natural Killer (NK) cells) via the Fc region, resulting in the lysis of the target cell. More

The Importance of Accurate Determination of ADCC Activity During Biosimilar Development

Category: Biosimilars

Tags: ,

By: Stefan Termen, Technical Services Scientist,

Cells infected with enveloped viruses will express viral proteins on their cell membranes, and many cancer cells will express specific surface antigens. These proteins are recognized by antibodies of the humoral immune system as targets for Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). In this process, effector cells of the immune system recognize the bound antibodies through their More

Cost and Time Effective Approach to Early Stage Biosimilar Development: A Case Study of Tocilizumab

Category: Biosimilars

Tags: , ,

By: Dr Terry Gray, Field Marketing Manager,

Introduction to Tocilizumab (Actemra) Tocilizumab (Actemra (US)/RoActemra (EU)) is a therapeutic monoclonal antibody that targets the Interleukin-6 receptor (IL-6R).  Interleukin-6 (IL-6) is a multifunctional cytokine which is central to the regulation of the immune and nervous systems.  This molecule has been linked to pathogenesis of several autoimmune diseases including rheumatoid arthritis (RA) due to aberrations More

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy